Suchergebnisse - "Mu, Guangyan"

PubPharm (8)

1

Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation : A multicentre prospective cohort study

enthalten in: Clinical and translational medicine | 2023

von Xiang, Q. | Wang, Z. | Mu, G. | +18

2

Integrated Pharmacokinetics/Pharmacodynamics Model and Simulation of the Ticagrelor Effect on Patients with Acute Coronary Syndrome

enthalten in: Clinical pharmacokinetics | 2023

von Liu, Z. | Liu, Y. | Mu, G. | +16

3

Identification of genetic biomarkers associated with pharmacokinetics and pharmacodynamics of apixaban in Chinese healthy volunteers

enthalten in: Expert opinion on drug metabolism & toxicology | 2023

von Mu, G. | Xie, Q. | Liu, Z. | +13

4

Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic-pharmacodynamic profiles of rivaroxaban

enthalten in: Human genomics | 2022

von Zhang, H. | Zhang, Z. | Liu, Z. | +10

5

Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation : A nationwide multicentre prospective cohort study

enthalten in: Clinical and translational medicine | 2022

von Xiang, Q. | Xie, Q. | Liu, Z. | +15

6

PROK2, HRNR, and FIG4 as potential genetic biomarkers of high bleeding propensity in East Asian patients with acute coronary syndrome using ticagrelor

enthalten in: Pharmacotherapy | 2022

von Xiang, Q. | Wang, Z. | Mu, G. | +11

7

Effect of Genetic Polymorphism Including NUP153 and SVEP1 on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects

enthalten in: Clinical drug investigation | 2022

von Xiang, Q. | Liu, Z. | Mu, G. | +10

8

Target Drug-Calibrated Anti-Xa Activity Assays and Expected Peak-Trough Levels in an Asian Population : A Multicenter Study

enthalten in: American journal of cardiovascular drugs : drugs, devices, and other interventions | 2021

von Liu, Z. | Xie, Q. | Zhang, H. | +6

1
[1]